FDA Places Partial Hold on Biohaven’s BHV-7000 Epilepsy Studies
The FDA has paused new patient enrollment in Biohaven’s BHV-7000 epilepsy studies after rodent findings. Dosing continues for current participants.
/ 1647 items
#XY↓
Major Novartis Shareholder Calls for Board Shake-Up After Two Failed Drug Trials
Artisan Partners wants Novartis board changes after Avidity’s del-desiran and pelacarsen failed late-stage trials and wiped out $30B in value.
Opus Genetics Jumps After Early Gene Therapy Data Show Vision Gains in All 5 Patients
Low-dose OPGx-BEST1 improved vision in all 5 patients and looked safe. Opus plans a higher-dose readout in Q2 2027 and Phase 3 in 2027.
Compass Pathways Rises After 1-Year Psilocybin Data in Treatment-Resistant Depression
Open-label Part C data showed extra MADRS improvement and ~30% remission after another 25 mg dose. Safety was unchanged. Launch targeted for H1 2027.
Summit Therapeutics Upgraded to Buy by Jefferies on Late-2026 PFS Outlook
Analysts see a likely PFS win in HARMONi-3 later in 2026.
MICVO’s Response Rate Slipped — and So Did PYXS
Confirmed responses fell from 46% (n=13) to 36% (12/33). Data beat old 2L chemo rates, yet safety, distant catalysts and financing overhang hit the stock.